论文部分内容阅读
目的:观察孟鲁斯特联合布地奈德治疗支气管哮喘患儿的临床疗效。方法:选取支气管哮喘患儿116例,随机分为对照组与观察组各58例,对照组患儿采用临床常规治疗措施,观察组患儿在对照组基础上采用孟鲁斯特联合布地奈德治疗,观察两组患者的临床疗效。结果:观察组患儿PEF、FVC及FEV1明显优于对照组,差异具有统计学意义(P<0.05);两组患儿不良反应发生率比较差异无统计学意义(P>0.05)。结论:孟鲁斯特联合布地奈德治疗支气管哮喘患儿疗效较好,能有效改善患儿肺功能,且无明显不良反应发生,值得临床推广应用。
Objective: To observe the clinical efficacy of monastuside combined with budesonide in the treatment of children with bronchial asthma. Methods: A total of 116 children with bronchial asthma were randomly divided into control group and observation group (58 cases each). The control group received routine clinical treatment. The children in observation group were treated with montelukast and budesonide Treatment, observe the clinical efficacy of two groups of patients. Results: The PEF, FVC and FEV1 in the observation group were significantly better than those in the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: Montelukast combined with budesonide in the treatment of children with bronchial asthma better curative effect, can effectively improve children’s lung function, and no significant adverse reactions, is worthy of clinical application.